Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury.

Flor María Fernández-Gordón SánchezElena Gómez-DomínguezDiana Paredes RuizYolanda Rodríguez GilAna Martín AlgíbezInmaculada Fernández VázquezPilar Martínez Montiel

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2022)

Pembrolizumab, a programmed cell death receptor (PD-1) inhibitor, have improved the prognosis in several types of cancer. Despite the important clinical benefits, checkpoint inhibition have been associated with inflammatory and immune-related side effects (irAE).

Keyphrases

liver injury
drug induced
advanced non small cell lung cancer
papillary thyroid
dna damage
squamous cell
cell cycle
oxidative stress
epidermal growth factor receptor
lymph node metastasis
ulcerative colitis
childhood cancer